The trial investigates the efficacy of combining venetoclax with the standard treatment of ivosidenib and azacitidine in patients with newly diagnosed IDH1-mutated AML or MDS/AML who are ineligible for intensive chemotherapy. The market for AML treatments is competitive, with several existing therapies, including targeted agents and hypomethylating agents. Should the combination therapy demonstrate improved outcomes, it could capture significant market share, particularly among older patients and those with comorbidities who are unable to tolerate intensive chemotherapy. The collaboration with multiple European study groups enhances the trial's credibility and recruitment potential, positioning it favorably in the competitive landscape.